Taysha Gene Therapies, Inc.

Healthcare

NASDAQ:TSHA · NASDAQ Global Select

Market Cap $1.61B Beta 1.18 P/E (TTM) -17.7

$6.42 +1.53%

+$0.10 today

52W Low $2.25High $7.30

Vol 6.25M · Avg 2.73M

EPS (TTM) -$0.35Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+157.83%

Period High

$6.98

Period Low

$2.31

Latest

$6.42

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Dianthus Therapeutics, Inc.

NASDAQ:DNTH

$3.35B

Enliven Therapeutics, Inc.

NASDAQ:ELVN

$2.75B

AnaptysBio, Inc.

NASDAQ:ANAB

$2.39B

Atai Beckley Inc.

NASDAQ:ATAI

$1.48B

Immatics N.V.

NASDAQ:IMTX

$1.29B

Nektar Therapeutics

NASDAQ:NKTR

$1.17B

Xencor, Inc.

NASDAQ:XNCR

$933.44M

Sana Biotechnology, Inc.

NASDAQ:SANA

$850.18M

Oculis Holding AG

NASDAQ:OCS

$636.30M

BridgeBio Oncology Therapeutics Inc.

NASDAQ:BBOT

$609.62M

What is the latest TSHA filing?

The latest filing shown is 4 dated Jun 2, 2026.

How many recent filings does TSHA have?

Intrinsic Alpha currently shows 20 recent filings for TSHA.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.